Rani Therapeutics (RANI) News Today $1.17 +0.02 (+1.74%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.25 +0.08 (+7.18%) As of 04/17/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Rani Therapeutics management to meet virtually with Lake StreetApril 17 at 9:20 AM | markets.businessinsider.comWhat is Zacks Small Cap's Estimate for RANI FY2025 Earnings?Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Equities researchers at Zacks Small Cap raised their FY2025 earnings per share (EPS) estimates for Rani Therapeutics in a note issued to investors on Tuesday, April 1st. Zacks Small Cap analyst J. Vandermosten now anticipates that theApril 5, 2025 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Rani Therapeutics in a research note on Thursday.April 5, 2025 | marketbeat.comRANI: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comEarnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024April 2, 2025 | investing.comRani Therapeutics (NASDAQ:RANI) Releases Earnings Results, Misses Estimates By $0.03 EPSRani Therapeutics (NASDAQ:RANI - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $1.03 million for the quarter.April 2, 2025 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPSRani Therapeutics (NASDAQ:RANI - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The firm had revenue of $1.03 million during the quarter.April 2, 2025 | marketbeat.comQ4 2024 Rani Therapeutics Holdings Inc Earnings CallApril 1, 2025 | finance.yahoo.comRani Therapeutics reports Q4 EPS (27c), consensus (23c)April 1, 2025 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comRani Therapeutics Reports 2024 Financial Results and UpdatesMarch 31, 2025 | tipranks.comRani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comRani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate UpdateMarch 31, 2025 | globenewswire.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Buy" from AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recMarch 31, 2025 | marketbeat.comAn Overview of Rani Therapeutics Hldgs's EarningsMarch 28, 2025 | benzinga.comTakeda Pharmaceutical Co. Ltd. Buys Shares of 203,190 Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)Takeda Pharmaceutical Co. Ltd. acquired a new stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 203,190 shares of the company'sMarch 28, 2025 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)March 28, 2025 | markets.businessinsider.comRani announces pharmacokinetic, pharmacodynamic data from RT-114 trialMarch 27, 2025 | markets.businessinsider.comRani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102March 26, 2025 | globenewswire.comRani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | globenewswire.comRani Therapeutics (RANI) Expected to Announce Quarterly Earnings on WednesdayRani Therapeutics (NASDAQ:RANI) will be releasing earnings before the market opens on Wednesday, March 19, Financial Modeling Prep reports.March 12, 2025 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have received a consensus rating of "Buy" from the six analysts that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating onMarch 5, 2025 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Large Increase in Short InterestRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,810,000 shares, an increase of 48.7% from the January 31st total of 1,890,000 shares. Currently, 12.4% of the shares of the company are short sold. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is presently 2.8 days.March 4, 2025 | marketbeat.comRani Therapeutics' (RANI) Buy Rating Reaffirmed at Canaccord Genuity GroupCanaccord Genuity Group reissued a "buy" rating and issued a $9.00 target price on shares of Rani Therapeutics in a research note on Wednesday.February 27, 2025 | marketbeat.comRANI: Impressive Bioavailability for RT-116February 18, 2025 | msn.comRani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last weekFebruary 15, 2025 | finance.yahoo.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Buy" from AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been given an average recommendation of "Buy" by the six ratings firms that are currently covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strongFebruary 8, 2025 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Rani Therapeutics in a report on Friday.February 7, 2025 | marketbeat.comRani Therapeutics reports positive obesity treatment studyFebruary 6, 2025 | msn.comRani Therapeutics announces data from semaglutide via RaniPill capsule trialFebruary 6, 2025 | markets.businessinsider.comRani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HCFebruary 6, 2025 | markets.businessinsider.comRani Therapeutics (NASDAQ:RANI) Stock Price Up 0.7% - Here's WhyRani Therapeutics (NASDAQ:RANI) Trading 0.7% Higher - Here's What HappenedFebruary 5, 2025 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Price Target from AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation tJanuary 17, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Mediwound (MDWD)January 14, 2025 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Rating of "Buy" by AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been given an average recommendation of "Buy" by the seven brokerages that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buyJanuary 14, 2025 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Buys $29,993.20 in StockDecember 17, 2024 | insidertrades.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Kate Mckinley Acquires 17,960 SharesRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) insider Kate Mckinley purchased 17,960 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $1.67 per share, for a total transaction of $29,993.20. Following the completion of the transaction, the insider now directly owns 17,960 shares of the company's stock, valued at $29,993.20. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.December 16, 2024 | marketbeat.comInsider Buying: Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) CEO Purchases 10,296 Shares of StockDecember 11, 2024 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), Trevi Therapeutics (TRVI) and Day One Biopharmaceuticals (DAWN)December 5, 2024 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Rating of "Buy" by AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the coNovember 25, 2024 | marketbeat.comWhat is Zacks Small Cap's Forecast for RANI FY2024 Earnings?Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Analysts at Zacks Small Cap raised their FY2024 earnings per share estimates for shares of Rani Therapeutics in a research note issued to investors on Wednesday, November 20th. Zacks Small Cap analyst J. Vandermosten now expects thatNovember 25, 2024 | marketbeat.comRANI: Third Quarter UpdateNovember 21, 2024 | finance.yahoo.comRani Therapeutics Advances in Biotherapeutics MarketNovember 19, 2024 | markets.businessinsider.comRani Therapeutics Holdings: Buy Rating Backed by Strong Financial Outlook and Strategic Focus on RT-114 ProgramNovember 19, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Rani Therapeutics (NASDAQ:RANI)HC Wainwright restated a "buy" rating and issued a $9.00 price objective on shares of Rani Therapeutics in a research report on Tuesday.November 19, 2024 | marketbeat.comMaxim Group Remains a Buy on Rani Therapeutics Holdings (RANI)November 15, 2024 | markets.businessinsider.comRani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate UpdateNovember 14, 2024 | markets.businessinsider.comRani Therapeutics Holdings Inc Class A RANINovember 10, 2024 | morningstar.comRani Therapeutics Holdings options imply 12.6% move in share price post-earningsNovember 10, 2024 | markets.businessinsider.comRani Therapeutics to Participate in Upcoming Investor ConferencesNovember 8, 2024 | finance.yahoo.com Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address RANI Media Mentions By Week RANI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RANI News Sentiment▼0.000.57▲Average Medical News Sentiment RANI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RANI Articles This Week▼12▲RANI Articles Average Week Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CMPS News OLMA News ARCT News AURA News ATAI News GLUE News SEPN News PVLA News ATYR News TSHA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RANI) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
